Tan Laboratory

Research Overview: 

Dr. Tan’s research focuses on developing and testing interventions that support informed decision-making and guideline-concordant screening uptake among patients. Currently, majority of her research focuses on lung cancer screening and adherence, including the psychosocial and clinical factors associated with lung cancer screening decisions, shared decision-making preferences, and lung cancer screening implementation in primary care settings.

Zhang Laboratory - Publications

View Dr. Zhang’s complete list of published work in NCBI MyBibliography

  1. Ahmari N, Choi K, Wu J, Rizvi TA, Jackson M, Kershner LJ, Kim MO, Zhang X, Dombi E, Shern J, Hildeman DA, Ratner N. Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas. Life Sci Alliance. 2025 Dec;8(12). doi: 10.26508/lsa.202503359. Print 2025 Dec. PubMed PMID: 40992926; PubMed Central PMCID: PMC12461152. 

Zhang Laboratory

.zhanglabaims { background-color: rgba(245, 245, 245, 1); padding: 1rem; border-radius:1rem; border: 1px solid #ccc; }

Research Overview

The Molecular Cancer Prevention Laboratory, led by Dr. Xiyuan Zhang at the Rutgers Cancer Institute, leverages genome-wide sequencing technologies to decipher the etiology and progression of pediatric sarcomas and cancer predisposition syndromes, particularly neurofibromatosis type 1 (NF1).